UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------------------------- ...

FibroGen, Inc. (NASDAQ:FGEN) Q2 2021 Results Conference Call August 9, 2021 5:00 PM ET Company Participants Michael Tung - Vice President of Corporate Strategy and Investor Relations Enrique Conterno - Chief Executive Officer Pat Cotroneo - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Thane Wettig - Chief Commercial Officer Chris Chung - Senior Vice President of China Operations Conference Call Participants Michael Yee - Jefferies Annabel Samimy - Stife ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------------------------- ...

FibroGen, Inc. (NASDAQ:FGEN) Q1 2021 Earnings Conference Call May 10, 2021 5:00 PM ET Company Participants Michael Tung - Vice President of Corporate Strategy and Investor Relations Enrique Conterno - Chief Executive Officer Pat Cotroneo - Chief Financial Officer Mark Eisner - Chief Medical Officer Thane Wettig - Chief Commercial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Annabel Samimy - Stifel Michael Yee - Jefferies Edwin Zhang - H.C. Wainwright Jason Gerbe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------------------------ ...

FibroGen, Inc. (NASDAQ:FGEN) Q4 2020 Earnings Conference Call March 1, 2021 5:00 PM ET Company Participants Michael Tung – Investor Relations Executive Enrique Conterno – Chief Executive Officer Mark Eisner – Chief Medical Officer Pat Cotroneo – Chief Financial Officer Conference Call Participants Joel Beatty – Citi Michael Yee – Jefferies Edwin Zhang – H.C. Wainwright Geoffrey Porges – SVB Leerink Annabel Samimy – Stifel Jason Gerberry – Bank of America Yaron Werber – Cowen Andy Hsieh – William Blair Difei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |--------------------------------- ...

FibroGen, Inc. Corporate Presentation November 2020 Forward-Looking Statements 2 This presentation contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, business strategy, and plans, and objectives of management for future operations, are forward looking statements. These forward-looking statements can generally be identifie ...

FibroGen, Inc. (NASDAQ:FGEN) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Michael Tung – Vice President-Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Pat Cotroneo - Chief Financial Officer Thane Wettig - Chief Commercial Officer Peony Yu - Chief Medical Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Michael Yee – Jefferies Annabel Samimy - Stifel Geoffrey Porges - SVB Leerink Yaron Werber - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------------------------- ...